Molecular Partners has finished the long retreat from a partnered infectious-disease story and is now a single-franchise radiopharmaceutical company whose remaining equity value sits on whether a designed ankyrin repeat protein can carry an alpha-emitting isotope into small-cell lung tumors without lighting up marrow or kidney. The mid-year clinical update is the first time that Radio-DARPin thesis has left the imaging suite and entered a United States dose-escalation study. Cohort one of MP0712 cleared its safety window at a starting activity of 75 MBq, with only transient low-grade events and no dose-limiting toxicity. That clearance is the event that matters; the half-year loss is just the cost of buying the next dose level.
The balance sheet still funds that experiment, but the clock is shorter than the year-end story implied. Cash and short-term deposits stood at CHF 68 million at mid-year. That pile is about $84 million after an operating cash use of CHF 25 million in the first half. Management restates the runway as lasting into late 2027. That is a pull-forward from the 2028 claim attached to the year-end cash pile. The compression is not a surprise after a zero-revenue half and a prior-year restructuring that thinned the workforce. Headcount fell from 153 roles to about 117. What it does change is the option set. There is now one clean readout window, not two, before the company is back in the capital markets.
The market already treats Molecular Partners as a cash-plus-option name. The Nasdaq line last printed near $4. That print implies a capitalization of about $161 million. Enterprise value sits near $96 million once cash is netted. That premium over cash is the entire Radio-DARPin franchise plus leftover immune-engager optionality. The question the rest of this year has to answer is whether the next dose level, and the first look at tumor versus organ uptake in treated patients, justifies paying anything above treasury value for a platform that has not yet shown a confirmed response.